Theravance Biopharma (TBPH) Misses Q1 EPS by 9c

Theravance Biopharma (NASDAQ: TBPH) reported Q1 EPS of ($0.35), $0.09 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $10.4 million versus the consensus estimate of $13.98 million.

For earnings history and earnings-related data on Theravance Biopharma (TBPH) click here.

You May Also Be Interested In

• After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
• Affirm Holdings (AFRM) Tops Q4 EPS by $3.77, Beats on Revenue
• Workday (WDAY) Tops Q2 EPS by 14c; offers outlook